On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research".
Prof. Clevers comments on founding HUB and describes the Company´s mission saying “We set up a non-profit foundation called Hubrecht Organoid Technology (HUB), which holds my lab’s patents. In addition to carrying out research, HUB offers licences for drug screening and access to organoids in its biobanks for pre-clinical drug discovery and validation.”
Pharmaceutical companies are using organoids derived from specific tumours to screen potential cancer drugs. A wide range of tissues are available for applications ranging from drug discovery to personalised medicine.
Contacts us to learn morecontact us